We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BMPS:MILBanca Monte dei Paschi di Siena S.p.A. Analysis

Data as of 2026-03-10 - not real-time

€7.39

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Valuation appears compelling: the price‑to‑earnings multiple is well below the sector average and the price‑to‑book ratio is under one, suggesting a significant discount. Dividend yield is in the double‑digit range and the payout ratio is moderate, making the stock attractive for income‑focused investors. Technical indicators show the stock is trading below its short‑term moving averages with a bearish MACD, yet the relative strength index sits near the oversold zone and volume is on the rise, hinting at potential short‑term upside. The current price is comfortably above the identified support level and well below the nearby resistance, offering a clear risk‑reward profile.
Recent corporate actions have bolstered the outlook: the acquisition of a controlling stake in Mediobanca and a net‑profit surprise have reinforced earnings momentum and positioned the bank for synergies. However, an insider‑trading probe involving a board member adds a layer of regulatory uncertainty, and the high 30‑day volatility underscores price swings. Overall, the blend of deep valuation discounts, strong dividend appeal, and improving earnings suggests a buy stance, tempered by medium‑term regulatory and market risks.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • oversold RSI indicating near‑term rebound potential
  • high dividend yield offering immediate income
  • price positioned above strong support with increasing volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • integration of Mediobanca stake could drive earnings
  • regulatory investigation may create uncertainty
  • moderate volatility may cause price fluctuations

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • deep valuation discount relative to peers
  • sustainable value proposition from low P/E and P/B
  • consistent high dividend yield supporting total return

Key Metrics & Analysis

Financial Health

Revenue Growth94.70%
Profit Margin59.54%
P/E Ratio4.8
ROE12.98%
ROA1.49%
P/B Ratio0.8
Industry P/E17.3

Technical Analysis

TrendNeutral
RSI35.2
Support€6.85
Resistance€9.03
MA 20€8.17
MA 50€8.64
MA 200€7.90
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Target Price€10.28
Upside/Downside39.03%
GradeUndervalued
TypeBlend
Dividend Yield12.21%

Risk Assessment

Beta0.66
Volatility42.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.